[144] ACM Research, Inc. SEC Filing
Form 144 notice for ACM Research, Inc. (ACMR) shows a proposed sale of 11,152 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $334,560.00. The shares represent a portion of 64,180,965 shares outstanding and an approximate sale date of 08/22/2025. The shares were acquired on 08/22/2025 by stock option exercise from the issuer and paid in cash. The filer reports no securities sold in the past three months and affirms they are not aware of any undisclosed material adverse information.
- Full compliance with Rule 144 disclosure elements: broker, share count, aggregate value, outstanding shares, acquisition method, and payment type are provided
- Clear acquisition detail: shares were acquired by stock option exercise and paid in cash
- No reported sales in the prior three months, simplifying aggregation calculations under Rule 144
- Filer attests they do not possess undisclosed material adverse information
- None.
Insights
TL;DR: Routine insider sale following exercise of options; modest size relative to outstanding shares, limited immediate market impact.
The filing documents a typical Rule 144 notice where the insider exercised options and intends to sell 11,152 shares via Morgan Stanley Smith Barney LLC on 08/22/2025 for an aggregate value of $334,560. The disclosure identifies the acquisition method (stock option exercise) and cash payment, and states no sales in the prior three months. For investors, this is a routine liquidity event rather than an operational update; the size disclosed is small relative to the 64.18 million shares outstanding.
TL;DR: Filing meets Rule 144 transparency requirements; includes acquisition details and seller attestation.
The notice includes required elements: broker name and address, number of shares, aggregate market value, outstanding shares, acquisition date and method, payment type, and the filer’s representation regarding material nonpublic information. The form contains no reports of prior sales in the past three months and includes the standard signature/attestation language warning about misstatements. This satisfies procedural governance expectations for an insider sale disclosure.